Market closedNon-fractional
Curis/CRIS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Curis
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Ticker
CRIS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Lexington, United States
Employees
49
Website
www.curis.com
Curis Metrics
BasicAdvanced
$35M
Market cap
-
P/E ratio
-$8.63
EPS
3.35
Beta
-
Dividend rate
Price and volume
Market cap
$35M
Beta
3.35
Financial strength
Current ratio
4.076
Quick ratio
3.793
Long term debt to equity
436.049
Total debt to equity
450.306
Interest coverage (TTM)
-34.27%
Management effectiveness
Return on assets (TTM)
-39.26%
Return on equity (TTM)
-207.29%
Valuation
Price to revenue (TTM)
3.394
Price to book
3.68
Price to tangible book (TTM)
72.62
Price to free cash flow (TTM)
-0.844
Growth
Revenue change (TTM)
-5.67%
Earnings per share change (TTM)
-21.67%
3-year revenue growth (CAGR)
-1.65%
3-year earnings per share growth (CAGR)
-3.41%
What the Analysts think about Curis
Analyst Ratings
Majority rating from 6 analysts.
Curis Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2M
-23.08%
Net income
-$12M
0.85%
Profit margin
-590.00%
31.11%
Curis Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.40
-$2.13
-$2.03
-$2.05
-
Expected
-$2.36
-$2.33
-$2.11
-$2.12
-$1.67
Surprise
1.69%
-8.43%
-3.97%
-3.39%
-
Curis News
AllArticlesVideos
Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
PRNewsWire·1 day ago
Curis to Present at Upcoming Healthcare Conference in July
PRNewsWire·2 weeks ago
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PRNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Curis stock?
Curis (CRIS) has a market cap of $35M as of July 27, 2024.
What is the P/E ratio for Curis stock?
The price to earnings (P/E) ratio for Curis (CRIS) stock is 0 as of July 27, 2024.
Does Curis stock pay dividends?
No, Curis (CRIS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Curis dividend payment date?
Curis (CRIS) stock does not pay dividends to its shareholders.
What is the beta indicator for Curis?
Curis (CRIS) has a beta rating of 3.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Curis stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.